Allergan Snaps Up Sydney Biotech for Upfront Payment of US $95M
Elastagen's revolutionary technology is based on recombinant human tropoelastin, the precursor of elastin which is a key component of youthful skin. Source: BioSpace
Teva's CGRP Migraine Med Hits a Stumbling Block
It's starting to feel like Teva can't catch a break. Source: BioSpace
Clinical-Stage Biotech Stock Might Outperform Amgen
This biotech could potentially could be a better value. Source: BioSpace
Teva CEO Says 2018 Will Be a Year of Falling Sales and Profits
Less than two months into the year, Teva's new chief has already effectively written off a recovery for 2018. Source: BioSpace
ImmunoPrecise Brings on New CEO
ImmunoPrecise announces the appointment of Dr. Jennifer Bath, as the new President and CEO of the Company effective February 21, 2018. Source: BioSpace
Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson
Syndesi will work to modulate the synaptic vesicle protein SV2A. Source: BioSpace
Novartis' Sandoz Jobs on the Chopping Block
The first of the pink slips at Sandoz' generic-drug manufacturing facility in Broomfield, Colo. have been handed out. Source: BioSpace
Boehringer Ingelheim Ditches Phase II Alzheimer's Program
Another potential treatment for Alzheimer's disease has been tossed into the rubbish bin. Source: BioSpace
Law Firm Seeks to Reopen Fraud Case Against Allergan Subsidiary
A Washington, D.C. law firm petitioned the U.S. Attorney’s Office in Boston to reopen an investigation of Forest Laboratories, claiming the company misrepresented clinical trial results used as the basis…
ViiV Healthcare Sues Gilead for Patent Infringement Following Approval of HIV Drug
ViiV Healthcare filed a patent infringement complaint against Gilead’s new HIV drug Biktarvy on the same day the combination drug secured the FDA’s approval. Source: Drug Industry Daily
- Go to the previous page
- 1
- …
- 172
- 173
- 174
- 175
- 176
- 177
- 178
- …
- 610
- Go to the next page